ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,917.11
0.00%
Dow Jones
43,408.47
0.32%
US Dollar vs MXN
20.33195
0.25%
Brent Oil
73.905
1.46%
Bitcoin
97,991.49
3.84%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Eupraxia Pharmaceuticals Inc (EPRX) Cotización

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc (EPRX)

Eupraxia Pharmaceuticals Inc
3.60
0.34
(10.43%)
Cerrado 20 Noviembre 3:00PM
Delayed by 15 minutes
3.60
0.00
( 0.00% )
Pre Mercado: 4:13AM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
3.60
Postura de Compra
3.60
Postura de Venta
3.90
Volume Operado de la Acción
58
0.00 Rango del Día 0.00
2.20 Rango de 52 semanas 4.08
Capitalización de Mercado [m]
128.241M
Precio Anterior
3.60
Precio de Apertura
-
Hora
2
@
3.8
Última hora de negociación
04:07:33
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
14,364
Acciones en circulación
35,622,553
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-6.35
Beneficio por acción (BPA)
-0.79
turnover
-
Beneficio neto
-28.22M

Acerca de Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient be... Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.eupraxiapharma.com
Sede
Victoria, British Columbia, Can
Fundado
-
Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was US$3.60. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of US$ 2.20 to US$ 4.08.

Eupraxia Pharmaceuticals currently has 35,622,553 shares in issue. The market capitalisation of Eupraxia Pharmaceuticals is US$128.24 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.35.

EPRX Últimas noticias

Más noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

22 horas hace
Edgar (US Regulatory)

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...

24 horas hace
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

14 Noviembre 2024
Edgar (US Regulatory)

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...

14 Noviembre 2024
PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

13 Noviembre 2024
Edgar (US Regulatory)

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

13 Noviembre 2024
PR Newswire (US)

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One...

12 Noviembre 2024
PR Newswire (US)

Form D - Notice of Exempt Offering of Securities

08 Noviembre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

07 Noviembre 2024
Edgar (US Regulatory)

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...

07 Noviembre 2024
PR Newswire (US)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.6120.40133779262.994.082.8540883.51904346CS
41.1446.34146341462.464.082.326303713.29965168CS
120.9435.33834586472.664.082.2143643.07092189CS
260.6522.03389830512.954.082.2150912.91193775CS
520.051.408450704233.554.082.2165752.89749301CS
1560.051.408450704233.554.082.2165752.89749301CS
2600.051.408450704233.554.082.2165752.89749301CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WORXSCWorx Corporation
US$ 1.85
(88.78%)
14.78M
AKTSAkoustis Technologies Inc
US$ 0.12985
(49.08%)
52.03M
PETWag Group Company
US$ 0.312
(48.50%)
16.27M
CRKNCrown Electrokinetics Corporation
US$ 1.13
(43.83%)
4.35M
ESGROEnstar Group Ltd
US$ 28.00
(40.92%)
24
WSBFWaterstone Financial Inc
US$ 9.00
(-40.98%)
4
TRSTriMas Corporation
US$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
US$ 11.00
(-40.15%)
208
XNCRXencor Inc
US$ 15.11
(-36.30%)
2
PYXSPyxis Oncology Inc
US$ 2.44
(-36.13%)
201.93k
AKTSAkoustis Technologies Inc
US$ 0.12985
(49.08%)
52.03M
PETWag Group Company
US$ 0.312
(48.50%)
16.27M
WORXSCWorx Corporation
US$ 1.85
(88.78%)
14.78M
XTKGX3 Holdings Company Ltd
US$ 0.0797
(-11.44%)
10.59M
CRKNCrown Electrokinetics Corporation
US$ 1.13
(43.83%)
4.35M

Discusión

Ver feed completo
WooptdooU WooptdooU 2 minutos hace
Don't forget the x poster "acted" as a shareholder rep and presented the CORPORATE WELFARIST, GRIFTER a TROPHY... don't forget that role...it might be brought up again...
LWLG
ExtremelyBullishZig ExtremelyBullishZig 2 minutos hace
The lost of people who look at things correctly. Stop taking psychedelics and you will see what is going on at Anavex.
AVXL
PonkenPlonken PonkenPlonken 3 minutos hace
are you drinking the kool aid or pushing the agenda?
Data will matter in the end and they went above and beyond to cheat on the ph2...
The insider buying on this is a non-factor.
SAVA
GBR GBR 3 minutos hace
Another article on AWS Multi Agent Orchestrator.


Sure reads like aiWARE capabilities to me, but if not involved, then don't know what to say about this partnership with AWS.

https://www.marktechpost.com/2024/11/19/aws-releases-multi-agent-orchestrator-a-new-ai-f
VERI
Ollori Ollori 3 minutos hace
Computer software has come such a long way, and it’s amazing to see the innovations happening every day. I’m particularly fascinated by AI tools and how they’re transforming industries, from customer service to graphic design. Recently, I started using project management software with AI integration
healthcare healthcare 3 minutos hace
https://www.prostavive.colibrip.com/ ProstaVive is an advanced supplement specifically crafted to support men’s prostate health, benefiting thousands across all age groups. With its potent, natural formula, ProstaVive promotes optimal prostate function, alleviates discomfort, and enhances urinary
NWBO
ksquared ksquared 3 minutos hace
FJB... Biden admin quietly loosening immigration policies before Trump takes office — including letting migrants skip ICE check-ins in NYC
By Jennie Taer Published Nov. 21, 2024, 5:59 a.m. ET Former acting Customs and Border Protection Commissioner Mark Morgan slammed the Biden administ
MrSmithLWLG MrSmithLWLG 4 minutos hace
They don’t have the pieces to the puzzle solved, they are not ready for commercialization, they are 12 months from $0.05. Proto and the pumpers are FLAT WRONG and I feel bad for KCC, Lebby has been playing him LIKE A FIDDLE.
LWLG
WooptdooU WooptdooU 4 minutos hace
The x and kcc posters must feel used and abused? Pity, really.
LWLG
StarryBuccaneer80 StarryBuccaneer80 4 minutos hace
Contact BitCoin.com Support Number +1(2O9)-798-6943 by Phone, simply go with This is the official support number where you can get assistance for any issues or questions related to BitCoin.com Account. This dedicated line connects you directly with BitCoin.com experts who can assist with all your pr
knrorrel knrorrel 4 minutos hace
$QBTS News is very good
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175418919
QBTS
uranium-pinto-beans uranium-pinto-beans 4 minutos hace
BJ
BJ's Wholesale reports Q3 adjusted EPS $1.18, consensus 93c
Reports Q3 revenue $5.1B, consensus $5.11B. Comparable club sales increased by 1.5% year-over-year. Comparable club sales, excluding gasoline sales, increased by 3.8% year-over-year, led by strong traffic. "Our third qua
Jake731 Jake731 4 minutos hace
Good morning y'all 😏




TPTW……!!!!!!!
TPTW
StarryBuccaneer80 StarryBuccaneer80 5 minutos hace
Contact MoonPay Support Number +I(2O9)-798-6943 by Phone, simply go with This is the official support number where you can get assistance for any issues or questions related to MoonPay Account. This dedicated line connects you directly with MoonPay experts who can assist with all your problem needs.
ExtremelyBullishZig ExtremelyBullishZig 5 minutos hace
That isn't the point. If a company gives 10 "artificial timelines" annually, andaybe delivers on one of them, they cannot be trusted toanage properly...it means they don't know how to manage projects...it is a problem.

If your wife constantly told you that she would be home from work
AVXL
StarryBuccaneer80 StarryBuccaneer80 5 minutos hace
Contact Metamask Support Number +1(53O)-447-2879 by Phone, simply go with This is the official support number where you can get assistance for any issues or questions related to Metamask Account. This dedicated line connects you directly with Metamask experts who can assist with all your problem nee
knrorrel knrorrel 5 minutos hace
great news, so the QUANTUM computer from QBTS can't be that bad, in fact the opposite, that it is a real quality product $QBTS and with yesterday's news that the quantum computer from QBTS is now 25,000 times faster than the other servers - simply brilliant

you might think that $QBTS
QBTS
WooptdooU WooptdooU 5 minutos hace
This leads back to the UNadmiral ship jumper, head of the compensation committee, GRIFT and Run guy...wonder where that, hahaha hero, learned that move?
LWLG
StarryBuccaneer80 StarryBuccaneer80 5 minutos hace
Contact Kraken Support Number +1(53O)-447-2879 by Phone, simply go with This is the official support number where you can get assistance for any issues or questions related to Kraken Account. This dedicated line connects you directly with Kraken experts who can assist with all your problem needs.
healthcare healthcare 6 minutos hace
https://neurozoom.colibrip.com/ NeuroZoom is the ultimate solution for complete support of healthy memory, concentration, and mental acuity. This cutting-edge formula is specifically designed to enhance brain function and boost cognitive performance. Packed with powerful ingredients, NeuroZoom he
NWBO
StarryBuccaneer80 StarryBuccaneer80 6 minutos hace
Contact Gemini Support Number +1-(2O9)-51O-5887 by Phone, simply go with This is the official support number where you can get assistance for any issues or questions related to Gemini Account. This dedicated line connects you directly with Gemini experts who can assist with all your problem needs.
knrorrel knrorrel 6 minutos hace
great news, so the QUANTUM computer from QBTS can't be that bad, in fact the opposite, that it is a real quality product $QBTS and with yesterday's news that the quantum computer from QBTS is now 25,000 times faster than the other servers - simply brilliant

you might think that $QBTS
QBTS
PC retired PC retired 6 minutos hace
Ah, zerogrid, thank you. On these cold winter days i do enjoy reading a bit of fiction to kill the boredom.
FLCX
uranium-pinto-beans uranium-pinto-beans 7 minutos hace
SNOW
Snowflake price target raised to $180 from $152 at Baird
Baird analyst William Power raised the firm's price target on Snowflake to $180 from $152 and keeps an Outperform rating on the shares. The firm said they reported strong Q3 results and with increasing confidence in the c
jimmybob jimmybob 7 minutos hace
GM FOLKSSS

Su Consulta Reciente

NASDAQ
EPRX
Eupraxia Pharmaceuticals
LSE
MBO
Mobilityone
LSE
IQE
Iqe
LSE
MIRA
Mirada
NASDAQ
INTC
Intel
BIT
ORS
Orsero
LSE
ASHR
Xhv Csi300
NYSE
MMM
3M
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados